Delivering mitochondrial health
The US patient organization United Mitochondrial Disease Foundation (UMDF) is hosting its annual Mitochondrial Medicine Symposium, this year virtual, in June. Abliva will participate in the scientific sessions: Chief Medical Officer, Magnus Hansson, will constitute one of the panelists, on Friday 25 June, at 1:50 p.m. EST, in the Clinical Trials Panel #2 Discussion, together […]
Italian patient organization Mitocon arranges this year's Mitochondrial Diseases Conference in virtual. Abliva's Chief Medical Officer, Magnus Hansson, will give a flash presentation and join round table discussions at the meeting.
Abliva will attend the virtual conference Mitochondrial Medicine - Therapeutic Development, organized by the Wellcome Connecting Science located at the Wellcome Genome Campus in the UK, on 30 Nov - 2 Dec 2021. Abliva's CMO, Magnus Hansson, has been invited to give a presentation on the topic Academia-pharma interplay in drug development, during Session 1: Mitochondrial […]
Abliva will attend and present at the Mitochondria-Targeted Drug Development Summit in Boston, MA, USA. The event will be held on 22 - 24 February 2022. CEO Ellen Donnelly will be presenting in the session Patient-Focused Drug Development for Mitochondrial Disease. Synopsis: Highlighting the impact of patient input on research and development at Abliva Providing […]
Abliva will participate at the United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium in Phoenix, Arizona. Abliva's CMO, Magnus Hansson, will participate in a panel discussion on clinical trials together with Baylor College of Medicine, Cyclerion Therapeutics, and Khondrion, on Friday June 10.
On June 29-30, Abliva will participate at Bioblast 2022: Inaugural Conference of Bioenergetics Communications in Innsbruck, Austria. Abliva's Communications Officer & Lab Manager, Eleonor Åsander Frostner, will present a summary of the company's recent preprint publication "Towards a treatment for mitochondrial disease: current compounds in clinical development".
In September, Abliva will attend mitoNice, an international congress dedicated to Mitochondrial Medicine.
In October, Abliva will attend the Italian patient organization Mitocon's annual Mitochondrial Diseases Conference in Rome, Italy. On October 8, Abliva's Chief Medical Officer Magnus Hansson will give the talk: An adaptive, clinical Phase 2/3 study evaluating the efficacy of KL1333 in adult primary mitochondrial disease patients in Session 5: Challenges and pitfalls in clinical […]
In late November, Abliva will attend the annual scientific conference Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. Abliva's Chief Medical Officer, Magnus Hansson, will present a poster on one of the important preparatory studies for the upcoming, potentially registrational, Phase 2 study, FALCON, with KL1333 in patients with mitochondrial diseases.
In June, Abliva will attend this year's edition of Euromit - the international conference on mitochondrial disease. The meeting takes place in Bologna, Italy, and gathers researchers, clinicians, and patients for the sharing of knowledge and insights in the field. The conference also presents opportunities to meet with investigators in our FALCON study with KL1333.
In late June, Abliva will be attending this year's international Mitochondrial Medicine Symposium, organized by US patient organization United Mitochondrial Disease Foundation. The meeting will take place in Charlotte, North Carolina (US), on June 28 - July 1, and includes both scientific as well as patient and family sessions.
